Agenus Makes Senior Regulatory and Clinical Appointments
LEXINGTON, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) — Agenus (NASDAQ:AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced the appointment of Patricia Carlos as Chief Regulatory, Quality, and Safety Officer; Todd Yancey, MD as Global Clinical Development, Medical Affairs and Commercial Development Advisor.
Related news for (AGEN)
- Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development Officer
- 24/7 Market News Snapshot 12 May, 2025 – Agenus Inc. (NASDAQ:AGEN)
- 24/7 Market News Snapshot 12 May, 2025 – Agenus Inc. (NASDAQ:AGEN)
- Agenus Reports Q1 2025 Financial Results and Key Business Updates
- Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program